Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-men proof of concept study of SAAP-148

Trial Profile

A first-in-men proof of concept study of SAAP-148

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2018

At a glance

  • Drugs SAAP 148 (Primary)
  • Indications Burn infections; Diabetic foot ulcer; Methicillin-resistant Staphylococcus aureus infections; Wound infections
  • Focus Adverse reactions; First in man; Proof of concept
  • Most Recent Events

    • 11 Sep 2018 New trial record
    • 27 Aug 2018 According to a Madam Therapeutics media release, the trial will initiate early in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top